Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CEST

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ASTELLAS PHARMA INC
04/29DJSanofi Seeks Talks With Medivation Over $9.3 Billion Offer
04/29DJCancer Drugs Entice Big Buyers -- WSJ
04/28DJDrugmakers Place Big Bets on Cancer Medicines
04/28 Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation
04/28 ASTELLAS PHARMA : Announces Changes to Representative Director and Audit & Super..
04/28 ASTELLAS PHARMA : Co-sponsors C3 Prize
04/28DJSanofi Makes $9.3 Billion Bid for U.S. Cancer-Drug Maker
04/22 SEATTLE GENETICS : Agensys, Seattle Genetics Assigned Patent
04/21 ASTELLAS PHARMA : CHMP Issues Positive Opinion to Include New Data in European L..
04/21 NEW DRUG DEVELOPMENT STUDY FINDINGS : Role of...
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials